Variant · Expression
ESR1 Expression
CI-VAR-00001063Explore in graph →CIViC 5435
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 32062536
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm1 | ||||||||
| NOT ERBB2 Overexpression AND ( PGR Expression OR ESR1 Expression ) | Everolimus/Exemestane Regimen | Predictive | B | Supports Sensitivity Response | 2 | submitted | EID12909In the multicenter open-label single-arm non-interventional STEPAUT study of postmenopausal women with HR+, HER2− advanced breast cancer progressing or recurring on/after prior NSAIs (n = 236), the HR… (full text at CIViC) PMID 32062536 · Steger et al., 2020 · Open in CIViC | civic |
| Estrogen Receptor-positive Breast Cancer2unmapped disease | ||||||||
| ESR1 Expression | Everolimus/Exemestane Regimen | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID12907In the same open-label randomized phase II BOLERO-6 trial (NCT01783444; n = 309), everolimus plus exemestane (n = 104) did not support improved PFS versus capecitabine monotherapy (n = 102) in ER+/HER… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available